应用促黄体生成素释放激素激动剂治疗子宫肌瘤的初步经验

A PRELIMINARY STUDY ON TREATMENT OF UTERINE LEIOMYOMA WITH A LEUTEINIZING HORMONE-RELEASING HORMONE AGONIST

12例子宫肌瘤患者,自月经局期第1天起,每天肌注促黄体生成素释放激素激动剂(LHRH-A)100 μg,连续4个月。所有病例用药后子宫及子宫肌瘤明显缩小,月经量减少。用药后血清雌二醇(E_3)水平明显下降,血清促性腺激素(FSH、LH)、血脂(高密度脂蛋白、胆固醇、甘油三脂)、骨皮质X线征等无明显变化。副作用轻微。按上法用药4个月,随访至停药后平均5.3月(3～11月),结果提示LHRH-A是保守性治疗子宫肌瘤有效而安全的药物。

Twelve cases of uterine leiomyoma were treated with leuteinizing hormone-releasing hormone(LHRH)agonist(D-Ala8-EA10). Drug treatment was commenced on the first day of the menstrual cycle at a dose of 100μg i. m. daily for 4 months. After the treatment, uterine as well as tumor sizes were reduced significantly (P< 0.01) and excessive metrorrhagia subsided in all 12 patients. Sarum estradiol(E2) levels showed significant reduction(P<0.01), while serum FSH, LH, lipoproteinw (high density lipoprotein, cholesterol and triglyceride) and x-rays of the hand and wrist bones showed no significant changes. Side effects were mild, results in our patients treated as above for 4 months and followed up for 6.3 months in average (3- 11 months) suggest that LHEH agonist appears to be ah effective and safe remedy for the conservative management of uterine leiomyoma.